CAS No. |
162808-62-0 |
中文名称 |
(10R,12S)-N-((2R,6S,9S,11R,12S,14aS,15S,20S,23S,25aS)-20-((R)-3-氨基-1-羟基丙基)-12-((2-氨基乙基)氨基)-23-((1S,2S)-1,2-二羟基-2-(4-羟基苯基)乙基)-2,11,15-三羟基-6-((R)-1-羟基乙基)-5,8,14,19,22,25-六氧代四十四氢-1H-二吡咯并[2,1-c:2',1'-l][1,4,7,10,13,16]六氮杂环二十一烯-9-基)-10,12-二甲基十四烷酰胺 |
英文名称 |
(10R,12S)-N-((2R,6S,9S,11R,12S,14aS,15S,20S,23S,25aS)-20-((R)-3-amino-1-hydroxypropyl)-12-((2-aminoethyl)amino)-23-((1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl)-2,11,15-trihydroxy-6-((R)-1-hydroxyethyl)-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl)-10,12-dimethyltetradecanamide |
别名 |
CS-1171;Caspofungine;CASPOFUNGIN;CASPORFUNGIN;PneuMocandin B0,1-[(4R,5S)-5-[(2-aMinoethyl)aMino]-N2-(10,12-diMethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-;Caspofungin MK-0991;Aids058650;Aids-058650 |
标准英文名 |
(10R,12S)-N-((2R,6S,9S,11R,12S,14aS,15S,20S,23S,25aS)-20-((R)-3-amino-1-hydroxypropyl)-12-((2-aminoethyl)amino)-23-((1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl)-2,11,15-trihydroxy-6-((R)-1-hydroxyethyl)-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl)-10,12-dimethyltetradecanamide |
分子式 |
C52H88N10O15 |
分子量 |
1093.33
|
精确分子量 |
1092.64
|
SMILES |
CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)C2=CC=C(O)C=C2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O |
标准SMILES |
CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN |
用途 |
Caspofungin is indicated for the following uses:
1. Empirical therapy for presumed fungal infections in febrile, neutropenic patients (defined as fever >38°C with an absolute neutrophil count [ANC] ≤500 cells/mL or ANC ≤1000 cells/mL with a predicted decline to ≤500 cells/mL);
2. Treatment of invasive candidiasis, including candidemia, intra-abdominal abscesses, peritonitis, and pleural space infections caused by Candida species;
3. Treatment of esophageal candidiasis, particularly in patients who are refractory to or intolerant of other antifungal therapies;
4. Salvage therapy for invasive aspergillosis in patients who are refractory to or intolerant of other antifungal agents such as voriconazole.
Additionally, caspofungin is recommended by clinical guidelines (e.g., IDSA and Chinese Society of Critical Care Medicine) as a first-line agent for candidemia and as prophylaxis or targeted therapy for invasive fungal infections in critically ill patients. |
InChIKey |
JYIKNQVWKBUSNH-WVDDFWQHSA-N |